# PHASE II, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PROSTVAC (PSA-TRICOM) IN PATIENTS... (PROTOCOL UAZ2012-03-01). CONTRACTOR: UNIVERSITY OF ARIZONA. CONTRACT: HHSN261201200031I. PERIOD: 9

> **NIH NIH N01** · UNIVERSITY OF ARIZONA · 2020 · $168,543

## Abstract

The contractor will conduct a phase II randomized, placebo-controlled, double-blind trial of PROSTVAC in patients with clinically localized prostate cancer undergoing active surveillance to assess the immunological (primary) and clinical (secondary) response to this vaccine.

## Key facts

- **NIH application ID:** 10207321
- **Project number:** 261201200031I-P00007-26100006-1
- **Recipient organization:** UNIVERSITY OF ARIZONA
- **Principal Investigator:** SHERY CHOW
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $168,543
- **Award type:** —
- **Project period:** 2014-09-12 → 2020-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10207321

## Citation

> US National Institutes of Health, RePORTER application 10207321, PHASE II, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF PROSTVAC (PSA-TRICOM) IN PATIENTS... (PROTOCOL UAZ2012-03-01). CONTRACTOR: UNIVERSITY OF ARIZONA. CONTRACT: HHSN261201200031I. PERIOD: 9 (261201200031I-P00007-26100006-1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10207321. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*